KonoSuba: Fantastic Days Celebrates Its First Anniversary With a 4 Star Legendary Festival Event
15.9.2022 04:02:00 EEST | Business Wire | Press release
KonoSuba: Fantastic Days, Nexon’s free-to-play mobile RPG, kicks off a two week celebration in honor of the game’s first anniversary. After battling for the last twelve months to defeat the villainous Devil King, our diligent heroes have earned the right to celebrate in festival events featuring premium gifts and rewards!
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220823005361/en/
#Nexon #NexonAmerica #KonoSuba (Graphic: Business Wire)
On top of the generous pre-registration bonuses offered earlier this month, and capping off a truly remarkable year in the world of Axel, KonoFans can expect a bounty of rewarding activities and gifts for their time spent in-game:
- 1st Anniversary Login Bonus (8/23 - 9/11): Free 10x Draw Ticket, up to 3000 Quartz, and more!
- New Main Quest and New Main Story (Part 2, Chapter 8)
-
New Story Event: “A Duet with This Crimson Demon Girl!”
- Players can experience Kazuma and Megumin's duet, "Bad Apple," during this event
- Participating in event missions allow you to get 3★ Lia (Dancing Announcer) for free!
-
1st Anniversary Ticket Draw (8/25 - 9/4):
- Tickets can be acquired from the 1st Anniversary Ticket Present event (8/16 - 8/29)
- Offers a chance to win 100,000 Quartz, 4★ Guaranteed Ticket, and more!
-
1st Anniversary Free 10x Recruit (8/23 - 9/3):
- Tickets can be acquired from 1st Anniversary related events/campaigns
- Offers a chance to get 1st Anniversary characters for free
-
1st Anniversary Legendary Adventurer Festival Recruit:
- Special Members
- 4★ Kazuma (Stage For Two)
- 4★ Megumin (Singing Sensation)
- Legendary Adventurer Festival Members
- 4★ Aqua (Legendary Adventurer)
- 4★ Darkness (Legendary Adventurer)
Based on the hit comedy anime series of the same name, KonoSuba: Fantastic Days was launched globally on August 19, 2021, on iOS and Android devices, after a successful release in Japan. The game focuses on a high school student (Kazuma) reincarnated to a fantasy world, where he is joined by a useless goddess (Aqua), an explosion fanatic (Megumin), and an unhinged crusader (Darkness) in their quest to fight the Devil King. Following the original storyline, the anime-based mobile title features brand new story content and exclusive heroes and heroines created specifically for the game. KonoFans have been able to battle as their favorite characters from the anime, all voiced by the original Japanese actors, including Jun Fukushima, Sora Amamiya, Rie Takahashi, and Ai Kayano.
Come celebrate in the wonderful, fantastical world of Axel!
KonoSuba: Fantastic Days is published by Nexon in partnership with KonoSuba publisher Kadokawa, and developed by Sumzap.
To stay up-to-date on KonoSuba: Fantastic Days, visit the Google Play or App Store page, and be sure to follow @PlayKonoSuba on Instagram and Twitter for the latest news!
Assets: Image Asset
Social Media: Twitch / Twitter / Instagram / Discord / Facebook
About KonoSuba: Fantastic Days konosuba.nexon.com
Based on the popular anime series “KonoSuba: God's Blessing on this Wonderful World!”, KonoSuba: Fantastic Days is a free-to-play character-collection RPG for iOS and Android. Featuring fan-favorite characters, including Kazuma Satou, Aqua, Megumin and Darkness, the game follows the storyline from the original novel and includes bespoke characters created exclusively for the game. Last year, the Japanese release of KonoSuba: Fantastic Days saw great success, garnering recognition from players and praise from the KonoSuba fan base.
About Nexon America Inc. https://www.nexon.com/
Founded in 2005, Nexon America Inc. delivers outstanding free-to-play online game expertise and live game support, taking the strengths of NEXON Co., Ltd. (“Nexon”) and applying them for uniquely western audiences. Nexon America has consistently sustained iconic franchises such as MapleStory and Mabinogi for more than a decade, which have gone on to break records and captivate players. With new projects on the horizon, Nexon America maintains the pioneering and innovative spirit of its parent company, employing its player-first approach, while designing the best possible gameplay experiences for the western market.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220823005361/en/
Contact information
Brian Klotz
Nexon America
NA_pr@nexon.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom